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Abstract 
The GLIS family zinc finger 3 isoform (GLIS3) is a risk gene for Type 1 and Type 2 
diabetes, glaucoma and Alzheimer’s disease endophenotype. We identified GLIS3 binding 
sites in insulin secreting cells (INS1) (FDR q<0.05; enrichment range 1.40-9.11 fold) sharing 
the motif wrGTTCCCArTAGs, which were enriched in genes involved in neuronal function 
and autophagy and in risk genes for metabolic and neuro-behavioural diseases. We confirmed 
experimentally Glis3-mediated regulation of the expression of genes involved in autophagy 
and neuron function in INS1 and neuronal PC12 cells. Naturally-occurring coding 
polymorphisms in Glis3 in the Goto-Kakizaki rat model of type 2 diabetes were associated 
with increased insulin production in vitro and in vivo, suggestive alteration of autophagy in 
PC12 and INS1 and abnormal neurogenesis in hippocampus neurons. Our results support 
biological pleiotropy of GLIS3 in pathologies affecting β-cells and neurons and underline the 
existence of trans-nosology pathways in diabetes and its co-morbidities. 
 
Keywords: Alzheimer's Disease, ChIP Sequencing, Diabetes Mellitus, Goto-Kakizaki Rat, 
Quantitative Trait Locus, Single Nucleotide Polymorphism 
Abbreviations: AD, Alzheimer's disease; Brown Norway; ChIPseq, genome-wide chromatin 
immunoprecipitation sequencing; DAVID, Database for Annotation, Visualisation and 
Integrated Discovery; G3BS, Glis3-binding sites; GK, Goto-Kakizaki; GLIS3, GLIS family 
zinc finger 3 isoform; GO, Gene Ontology; GWAS, Genome-wide association studies; IPA, 
Ingenuity Pathway Analysis; T2D, type 2 diabetes; 
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1. INTRODUCTION 
Genome-wide association studies (GWAS) for common inherited human diseases have shed 
light on novel candidate genes [1], which often lack functional characterisation to understand 
their role in disease pathogenesis. Growing evidence from GWAS data supports the 
involvement of common risk loci in diseases characterized by distinct pathophysiological 
features, suggesting that genes at these loci contribute to shared disease etiology through 
mechanisms of cross-phenotype association and pleiotropy [2, 3]. This phenomenon is 
illustrated with common risk loci in autoimmune and immune-mediated inflammatory 
diseases [4, 5], and recently extended to genetic variants shared in cancer and blood 
triglycerides and low-density lipoprotein cholesterol [6]. 
The GLIS family zinc finger 3 isoform (GLIS3) is among the most replicated GWAS signals 
for diabetes mellitus and related metabolic traits. It is one of the few identified GWAS risk 
genes for both type 1 [7-9] and type 2 [10-12] diabetes. GWAS have shown that common 
variants within GLIS3 itself are also associated with cerebrospinal fluid Tau [13], a 
biomarker in Alzheimer's disease, glaucoma [14] and serum levels of the thyroid stimulating 
hormone [15]. Patients with mutations in GLIS3 exhibit neonatal diabetes and congenital 
hypothyroidism [16, 17], but they also show a much broader spectrum of clinical 
manifestations, including hepatic, renal and cardiac diseases and skeletal abnormalities [16-
18]. These data strongly suggest that genetic variations and mutations in GLIS3 have strong 
cross phenotypic effects in distinct organs. 
GLIS3 is a component of Krüppel-like zinc finger transcriptional regulators that share a 
highly conserved five-C2H2-type zinc finger. It is expressed in many organs where it controls 
gene transcription through Glis3-binding sites (G3BS) in regulatory regions of target genes 
[19]. GLIS3 plays a critical role in the development and function of pancreatic β-cells, as 
shown for many type 2 diabetes GWAS genes [20]. Consistent with its primary etiological 
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role in diabetes, it regulates fasting glucose and insulin [21, 22] and glucose-stimulated 
insulin release [23]. Glis3 disruption in mice causes neonatal diabetes and hypothyroidism 
[24-26]. Glis3-null pups are hyperglycemic and die prematurely. Glis3 mutant mice exhibit 
small islets, with strongly decreased number of β- and δ-cells. Several studies indicate that 
Glis3 indirectly regulates expression of key transcription factors (Pdx1, NeuroD1, MafA) 
required for the development of the endocrine pancreas and the function of mature β-cells 
[24, 26, 27] and is implicated in β-cell survival [28]. 
Despite the key role of GLIS3 in diabetes etiology and in endocrine pancreas development, 
molecular and cellular mechanisms mediating its function remain largely unknown. To 
understand diabetes-related mechanisms regulated by GLIS3 in β-cells, we carried out 
genome-wide chromatin immunoprecipitation sequencing (ChIPseq) of G3BS in INS1 cells, 
which derive from rat pancreatic β-cells, followed by molecular and physiological studies 
(Figure 1). Results suggest that G3BS are enriched for GWAS loci associated with metabolic 
diseases and neuropathologies and that GLIS3 regulates the expression of genes involved in 
the function of endocrine pancreas and neurons, thus suggesting cross-phenotype associations 
of the GLIS3 locus. Further functional studies indicate that GLIS3 exhibits dual biological 
roles in β-cells and neurons possibly through differential expression of autophagy genes, 
which provide evidence for the involvement of mechanisms of biological pleiotropy in 
GLIS3 function. 
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2. MATERIALS AND METHODS 
2.1.  GLIS3 chromatin immuno-precipitation and sequencing 
About 1x10
7
 rat insulinoma 832/13 INS1 cells (gift from M LeGall, INSERM U872, Paris, 
France) were used. Proteins and DNA were cross-linked by addition of 0.4% formaldehyde 
(Sigma Aldrich, Saint Quentin Fallavier, France). Cells were washed with phosphate buffered 
saline (Sigma Aldrich, Saint Quentin Fallavier, France). Chromatin was collected by 
centrifugation and fragmented to generate DNA fragments of 200bp. Immunoprecipitation 
was performed with anti-GLIS3 antibody (Abcam, 51268, Cambridge, UK). DNA 
sequencing was performed on a genome analyzer GA-IIx (Illumina, Saffron Walden, UK). 
We obtained over 20M and about 37M reads in IP and Input, respectively. Raw sequence 
data have been deposited in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under the 
accession number E-MTAB-5454. 
Sequence alignment was performed using Bowtie. Peak calling performed with MACS2 
(https://github.com/taoliu/MACS/wiki/Install-macs2) identified 299 peaks with sizes ranging 
from 134nt to 1656nt. Peak sequences were searched for DNA motifs using Dimont, RSAT 
(Peak-motifs), GimmeMotifs and completeMotifs [29]. RSAT was used on the 299 sequences 
restricted to the 200bp around the peak summits. Motifs were considered as significant when 
binomial significance ≥ 10. Twelve tools were considered (Mdmodule, MEME, 
MotifSampler, trawler, Improbizer, BioProspector, Posmo, ChIPMunk, JASPAR, AMD, 
HMS, GADEM). For this analysis, 90% of the full-length sequences were used to predict 
motifs while 10% were used to compute p-values (only motifs with a p-value < 0.001 and 
enrichment > 1.5 were retained). CompleteMotifs was used to combine four different tools, 
PATSER, MEME, Weeder and ChiPMunk. One motif with the consensus sequence 
wrGTTCCCArTAGs was found in the top motifs of all four tools. 
2.2.  Cell systems 
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Rat insulinoma 832/13 INS1 cells were cultured in RPMI 1640 containing 10mM HEPES, 
11mM D-Glucose, 10% fetal bovine serum (FBS) (Life technologies, Saint Aubin, France), 
1mM sodium pyruvate, 2mM L-glutamine, 50µM β-mercaptoethanol and maintained in 5% 
CO2-95% O2 at 37°C. Rat insulin-producing INS-1E cells (passages 60 to 70, gift from Dr. 
C. Wollheim, Geneva, Switzerland), which were derived from INS1 [30], were cultured in 
RPMI 1640 GlutaMAX-I (Invitrogen, Carlsbad, CA). Rat pheochromocytoma PC12 cells 
(Sigma Aldrich, Saint Quentin Fallavier, France) were cultured in DMEM (Life technologies, 
Saint Aubin, France) containing 10% horse serum and 5% fetal bovine serum (Life 
technologies, Saint Aubin, France). Differentiation of PC12 cells was performed in a medium 
containing DMEM, 1% horse serum and NGF (100ng/ml). 
2.3. Animals 
Colonies of Goto-Kakizaki (GK/Ox) and Brown Norway (BN) rats were bred locally. The 
congenic strain BN.GK-Glis3-Ric1 (referred as BN.GK-1k throughout the text) was derived 
using a genetic marker assisted breeding strategy (“speed congenics”) and maintained as 
previously described [31]. This congenic was designed to contain GK alleles at the Glis3 
locus onto the genetic background of the BN strain. Rats were allowed free access to tap 
water and standard laboratory chow pellets (R04-40, Safe, Augy, France) and were 
maintained on a 12-h light-dark cycle. All experiments were carried out with six month old 
male congenic and control rats. All animal procedures were performed under a UK Home 
Office licence approved by the ethical review panel of the University of Oxford and 
authorised by the Charles Darwin Ethics Committee in Animal Experiment, Paris, France. 
2.4.  Glucose-induced insulin secretion in vivo 
Insulin secretion tests were performed by intravenous injection of glucose (0.8g /kg body wt) 
in rats fasted for 4 hours in the morning (post absorptive state) using the protocol applied to 
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the phenotypic screening of the GKxBN F2 hybrids [32]. Plasma immunoreactive insulin was 
assayed using an ELISA kit (Mercodia, Uppsala, Sweden). 
2.5.  Static incubation of pancreatic islets 
BN.GK-1k congenic and BN rats were killed by cervical dislocation. Collagenase (Sigma 
Aldrich, Saint Quentin Fallavier, France) was rapidly injected into the ligated pancreatic duct 
and pancreas was excised for pancreas digestion. Islets were isolated using a 
stereomicroscope. Insulin secretion was measured in static incubation following overnight 
culture in RPMI1640 containing 5mM glucose. Groups of 10 size-matched islets were pre-
incubated prior to treatment with 1, 12 and 20mM glucose. Islets were then incubated for 1 hr 
at 37°C and the supernatant removed for analysis. Insulin was assayed using an ELISA kit 
(Mercodia, Uppsala, Sweden). 
2.6. Glucose-induced insulin secretion in vitro in INS1 cells 
Rat insulinoma 832/13 INS1 cells were maintained in a glucose-free culture medium prior to 
incubation in a solution containing 2.8mM or 16.7mM of glucose. Immunoreactive insulin 
was determined by ELISA (Mercodia, Uppsala, Sweden) on supernatants and protein content 
was measured on cells. 
2.7.  Immunohistochemistry 
Pancreata from 4-weeks old Wistar rats were fixed in 4% paraformaldehyde and embedded in 
paraffin. Paraffin sections (7µm) were prepared. Adjacent sections were incubated with 
primary antibodies: guinea-pig anti-porcine insulin (1:1000, ICN pharmaceutical, Orsay, 
France), rabbit antirecombinant glucagon (1:1000, Vector, Peterborough, UK) or custom 
made anti-rat GLIS3 (1:1000, Eurogentec, Angers, France). 
2.8.  Primary cultures 
Hippocampi were dissected from embryonic day 18 or 19 Sprague Dawley rats. Tissue was 
trypsinized and neurons were plated at a density of 2.3 × 10
4
 cells/cm
2
. After attachment for 
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2–3 h, cells were incubated in Neurobasal medium supplemented with B27 (1×), L-glutamine 
(2 mM), and antibiotics (Invitrogen, Paisley, UK). 
2.9.  siRNA-mediated GLIS3 knock down in vitro and plasmid transfection assays  
Cultured INS-1E cells were transfected with control or GLIS3 siRNA and collected for 
Western blot analyses for microtubule-associated protein 1 light chain 3 (LC3) -I and LC3-II 
protein expression. Cells were exposed or not to carbamazepine (30μM) for 24 hours and 
apoptosis was determined with nuclear dyes. 
Glis3 cDNA from pancreatic islets were amplified from BN and GK animals and cloned into 
pcDNA3 (Invitrogen, Paisley, UK). INS1-cells were transfected by adding 50µl of OPTI-
MEM (Life technologies, Saint Aubin, France) containing plasmid (2µg) and Lipofectamine 
(2µl). NGF-PC12-cells were transfected by adding 50µl of OPTI-MEM containing plasmid 
(1µg) and lipofectamine (1µl). Primary culture hippocampal neurons were transfected in 
Neurobasal medium without supplements using lipofectamine LTX with Plus Reagent 
(Invitrogen, Paisley, UK) and plasmid (1μg). 
2.10. Imaging of cultured hippocampal neurons 
Experiments were carried out with cultured hippocampal neurons 72-96 h after transfection. 
Imaging was obtained on a Leica SP5 confocal microscope with a 40X water objective. The 
number of dendrite branches crossing concentric circles around the soma was automatically 
counted using Fiji Sholl analysis plugin. Spine density was determined manually using single 
cell labelling on 3 medial branches by neuron. 
2.11. Protein analyses 
Total protein extracts were transferred to nitrocellulose membranes and incubated with rabbit 
anti-GLIS3 (1:500, Eurogentec, Angers, France), mouse anti-actin (1:5,000, #3280, Abcam, 
Cambridge, UK), rabbit anti-LC3 (1:500, #4108; Cell signalling, St Quentin, France), -
tubulin (1:5,000; Cell signalling, St Quentin, France). The secondary antibodies used were 
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horseradish peroxidase-conjugated anti-mouse antibody (1:5,000, Sigma Aldrich, Saint 
Quentin Fallavier, France) and anti-rabbit (1:2,000, Sigma Aldrich, Saint Quentin Fallavier, 
France). For autophagy analysis, total protein extracts were transferred to polyvinylidene 
fluoride membranes and incubated with rabbit anti-LC3 and mouse anti-actin (1:400; Abcam, 
Cambridge, UK). The secondary antibodies used were horseradish peroxidase-conjugated 
rabbit anti-goat (1:50,000; Pierce, Cramlington, UK), goat anti-rabbit antibody (1:2,000; 
DAKO, Ely, UK) and goat anti-mouse (1:2,000; Pierce, Cramlington, UK). 
2.12. Glis3 sequencing and SNP validation  
Glis3 polymorphisms were validated by sequencing genomic DNA from BN and GK strains. 
PolyPhen-2 v2.2.2r398 (http://genetics.bwh.harvard.edu/pph2) [33] was used to predict the 
potentially damaging consequences of the polymorphisms found in Glis3. 
2.13. Real time quantitative PCR 
Total RNA was prepared with RNeasy kit (Qiagen, Crawley, UK). Real-time quantitative 
PCR (q-PCR) was performed on a Rotor Gene 6000 (Corbett Research, Milton, UK) and the 
results were normalized to the house keeping gene. cDNA was amplified by real-time q-PCR 
with Quantitect SYBR Green PCR mastermix (Qiagen, Crawley, UK). Four to six biological 
replicates were analysed and each sample was analysed in triplicate. Oligonucleotides 
designed for PCR are given in Table S1. 
2.14. Statistical analyses 
Statistical analyses were performed using SPSS software version 17.0.3 (SPSS UK, Chertsey, 
UK). Differences in continuous variables between groups were compared using Student's t-
tests or analysis of variance (ANOVA) with the LSD or Tamhane’s T2 test depending on 
whether Levene's test was insignificant or significant [p(L) < 0.05], respectively. 
2.15. Comparative genome analysis of G3BS and relationships to GWAS 
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Analysis of synteny conservation between rat and human genomes was carried out for genes 
associated with 163 of the 169 G3BS clusters defined in Table S2. Comparative analysis of 
genes directly associated with GLIS3 binding sites in the rat and human genomes was used as 
initial anchor synteny points in the two species, which were further ascertained using the 
genomic position of flanking genes. We considered human orthologs flanking G3BS, and 
immediately adjacent genes when mapped within 100Kb of G3BS (Table S3), to search for 
statistically significant genetic association with diseases and disease intermediate phenotypes 
in the GWAS archive (www.ebi.ac.uk/gwas). All GWAS loci that we searched in this 
catalogue were statistically significant, ie. supported by a p-value <1.0 x 10
-5
 in the overall 
(initial GWAS and replication) population (www.ebi.ac.uk/gwas/docs/methods). Details of 
categorisation of intermediate phenotypes relevant to common diseases are given in Table S4. 
2.16. Pathway analysis of genes associated with GLIS3 binding sites. 
The list of genes associated with GLIS3 binding sites were submitted to Ingenuity Pathway 
Analysis (IPA, http://www.ingenuity.com) for pathway enrichment analysis and to the 
Database for Annotation, Visualisation and Integrated Discovery (DAVID, 
https://david.ncifcrf.gov) for gene functional annotation using Gene Ontology (GO) terms. 
IPA and DAVID top ranked pathways and functional group of genes to be studied were 
selected based on the rank, the score and the p-value. Since this is an exploratory approach, 
and the main pathways identified were independently validated experimentally, the p-values 
displayed were not corrected for multiple testing.  
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3. RESULTS 
3.1.  GLIS3-mediated transcriptional landscape in β-cells 
To understand diabetes-related mechanisms regulated by GLIS3 in β-cells, we carried out 
genome-wide chromatin immunoprecipitation sequencing (ChIPseq) of GLIS3 binding sites 
(G3BS) in cultured insulin secreting INS1 cells. Read-enriched regions from the ChIP-Seq 
identified 299 putative G3BS (q<0.05; enrichment range 1.40-9.11 fold), which we grouped 
in 169 clusters (Table S2) evenly distributed across the genome (Figure S1). Over 65% of 
G3BS (195/299) and 70% of G3BS clusters (118/169) which could be mapped to the rat 
genome assembly were localised within 50kb of a protein coding sequence (Figure 2A). As 
expected, we showed that several genes close to G3BS are involved in β-cell development 
(Pdx1) and function (Insr, Kcnj6, Slc2a2) (Table S2). Quantitative PCR for a selection of 14 
genes chosen for their tight linkage to putative G3BS validated significant chromatin 
enrichment for 10 loci tested (Figure S2). 
Genomic sequences from the ChIP-Seq were searched for common DNA sequence motifs 
that could represent consensus binding sites for GLIS3. One motif with the consensus 
sequence, wrGTTCCCArTAGs was found in the top motifs of all four tools used (PATSER, 
MEME, Weeder, ChiPMunk). We confirmed the enrichment of previously proposed GLIS3 
binding motifs G(T/C)CCCC(T/A)GCTGTGA(A/G) and (G/C)TGGGGGGGT(A/C) using 
Find Individual Motif Occurences (FIMO) and MEME [34, 35] (Table S5). Sixty-eight 
occurrences of the former where found in 54 peak sequences (p-value < 0.0001) and eighteen 
occurrences of the latter where found in 14 peak sequences (p-value < 0.0001) (Table S5). In 
addition, based on our sequencing data, the motif wrGTTCCCArTAGs also emerged from all 
software used as a new consensus DNA sequence for G3BS (Figure 2B). 
3.2.  Biological pathway analysis suggests dual pathophysiological role of GLIS3 in β-
cells and neurons 
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We initially used function and pathway annotations available for genes containing or 
immediately adjacent to G3BS to predict functional aspects of GLIS3 biology. Results from 
Ingenuity Pathway Analysis (IPA) revealed its anticipated predominant role in metabolic 
function and diseases, even though the effects were not significant when corrected for 
multiple testing. A total of 60 genes associated with G3BS contributed to enrichment of 
functions involved in endocrine system development and function and in metabolic and 
endocrine system diseases (Table 1A). Interestingly, IPA also identified enrichment of 
functions directly relevant to other disease areas, including neurobiology through nervous 
system development and function (Table 1A). Results from DAVID pathway enrichment 
analysis (http://david.abcc.ncifcrf.gov) confirmed this finding with the identification of genes 
close to G3BS that contributed to statistically suggestive enrichment of the pathways synapse 
(Phactr1, Lzts1, Grik1, Grik3, Erc2, Insr, Nsf, Itpr1) (p=0.015), ion transport (Trpc4, Kcnj6, 
Grik1, Slc22a12, Grik3, Kctd3, Abcc2, Muc5ac, Nsf, Kcnip4, Itpr1) (p=0.008), cell projection 
part (Lzts1, Grik1, Slc22a12, Grik3, Slc2a2, Nsf, Gnat3) (p=0.008) and synaptic transmission 
(Hrh1, Grik1, Grik3, Erc2, Nsf) (p=0.049) (Table 1B). G-profiler also identified genes 
associated with G3BS contributing to the suggestive enrichment of the pathway neuron part 
(GO:0097458) (Kcnn4, Nsf, Baiap2, Grik1, Kcnj6, Fam5c, Erc2, Lzts1, Polr2m, Disc1, 
Anks1a, Plcb4, Lamp5, Src, Ghrh, Rheb, Gnat3, Itpr1, Grik3, Ephb1) (p=0.01). This 
unexpected finding obtained with insulin secreting cells INS1 is supported by co-expression 
of GLIS3 in brain, specifically in the hippocampus in the mouse (Figure 2C; Figure S3), and 
in pancreatic β-cells in the rat (Figure 2D). α-cells expressing glucagon were predominantly 
peripheral to the islets and evidence of co-straining for GLIS3 and insulin indicate that 
GLIS3 is expressed specifically in β-cells. These observations suggest that GLIS3 may also 
have a role in neuronal function and in diseases of the nervous system. Analysis of GLIS3 
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expression in the developing mouse brain supports its presence throughout hippocampal 
development (Figure S4). 
To assess dual etiological roles of GLIS3 in metabolic and neurological diseases, we searched 
genes localised close to G3BS in the NHGRI-EBI catalog of published GWAS 
(www.ebi.ac.uk/gwas) for evidence of association with disease status and disease 
intermediate phenotypes. Following analysis of synteny conservation of G3BS clusters 
defined in Table S3 in the human genome, we identified 375 cases of genetic associations 
between genes at 127 G3BS and various phenotypes and disease traits (Table 2, Table S3). 
Interestingly, even though genetic associations to cancer phenotypes in the GWAS archive 
are more frequent than those to any other disease category, we found a statistically significant 
(p<2.2 x 10
-16
) enrichment of G3BS linked to genes associated with phenotypes relevant to 
cardio-metabolic diseases (n=89 for 27,982 associations; OR=6.8) and neuro-behavioural 
pathologies (n=72 for 15,326 associations; OR=10.1) when compared to cancer (n=23 for 
49,324 associations). In a large number of cases (27), there was consistent association 
between genes at G3BS and both cardio-metabolic and neuropathological phenotypes. This 
finding was particularly significant for prime candidates for diabetes (Pdx1) or schizophrenia 
and Alzheimer's disease (Disc1) and replicated signals for different traits (eg. Macrod2, 
Grik1) (Table 2). 
3.3.  GLIS3 regulates gene transcription in β-cells and neurons 
To provide experimental evidence for GLIS3-mediated transcriptional regulation of genes 
associated with G3BS and to test the hypothesis that G3BS signals originally detected in 
insulin secreting cells also function in neurons, GLIS3 overexpression experiments were 
performed with INS1 cells and with PC12 cells, which derive from a pheochromocytoma of 
the rat adrenal medulla and can differentiate into neurons upon NGF stimulation. We selected 
candidate genes for quantitative RT-PCR analysis on the basis of two criteria: their 
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association or close physical proximity to a putative G3BS and their known functional role in 
these cell types. GLIS3 stimulated expression in INS1 was associated with significant 
overexpression of Ap3s1, Stxbp4, Bicd1 and Nxph2 and reduced expression of Atg7, Angptl3, 
Disc1, Dock7, Slit3 and Fbxw11 (Figure 3A). Replication of statistically significant gene 
transcription changes in neuronal cells PC12 stimulated by GLIS3 was limited to 
downregulated expression of Disc1 (Figure 3B). Dock7 was also downregulated by GLIS3 in 
both INS1 and PC12, but the differences were not significant in PC12 cells. On the other 
hand, GLIS3 stimulation was associated with significantly enhanced transcription of Atg4a 
(Figure 3B), which was not evidenced in INS1 (Figure 3A). These results indicate that GLIS3 
regulates gene transcription in both β-cells and neurons. Even though different collections of 
genes may be controlled by GLIS3 in the two cell types, our data suggest convergence to 
autophagy mechanisms through different genes in β-cells (Atg7) and neurons (Atg4a). 
3.4. Glis3 regulates the expression of genes involved in autophagy 
Results from pathway analysis also pointed to molecular mechanisms that may explain cross 
phenotype association mediated by GLIS3. Using DAVID (http://david.abcc.ncifcrf.gov), we 
showed that Atg4c, Atg7 and Atg12, which contain, or are immediately adjacent to, G3BS 
contributed to suggestive enrichment of the pathway autophagy (GO:0006914; Enrichment 
Score 1.46; p=0.01) (Table 1), a fundamental mechanism that degrades cytoplasm 
constituents. The pathway regulation of autophagy in KEGG (rno04140) was also the top 
ranking pathway enriched when analyses were carried out with DAVID (p=0.018) and G-
profiler (p=0.05). GLIS3-mediated regulation of autophagy in both β-cells and neurons was 
supported by cell-specific GLIS3-reactive transcription of Atg7 and Atg4a in INS1 and PC12 
(Figure 3A,B). 
To establish the regulatory role of GLIS3 in autophagy, we initially quantified autophagic 
markers LC3-I and LC3-II in INS1 and PC12 overexpressing Glis3 (Figure 3C,D). 
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Stimulated expression of Glis3 was associated with significantly increased LC3-II abundance 
and in LC3-II/LC-I ratio in INS1 cells (Figure 3C), suggesting enhanced autophagy. We 
subsequently repeated the experiment in INS-1E cells treated with siRNA designed to 
downregulate Glis3 expression. Transfection of INS-1E cells by siRNA targeting Glis3 
resulted in a 50% reduction in Glis3 mRNA level (Figure 3E). SiRNA-mediated GLIS3 
knock-down was associated with a significant decrease in abundance of LC3-I and LC3-II 
(Figure 3E). In contrast, stimulated expression of Glis3 in PC12 cells was associated with 
significant reduction of both abundance of LC3-I and LC3-II and conversion of LC3-I to 
LC3-II (Figure 3D). To examine whether stimulating autophagic flux would protect beta-
cells, we used the autophagy-enhancing drug carbamazepine [36], which may promote 
increased clearance of autophagosomes [37]. Carbamazepine had no effects on apoptosis in 
INS-1E cells treated with control siRNA, but was associated with significant protection of 
INS-1E cells from apoptosis secondary to Glis3 knock down. These results indicate that 
defective autophagy indeed contributes to cell death observed in the context of Glis3 
inhibition (Figure 3F). 
3.5.  Naturally-occurring polymorphisms in Glis3 affect gene expression and autophagy 
regulation in β-cells and neurons 
Using our published genome sequence data in the Goto-Kakizaki (GK) rat model of type 2 
diabetes [38], we identified two non-synonymous naturally-occurring polymorphisms 
(R356C and S851P) in the Glis3 sequence (Figure S5a). Variants R356C and S851P were 
respectively predicted as probably and possibly damaging by the PolyPhen-2 program 
(http://genetics.bwh.harvard.edu/pph2/) (Figure S5b,c). The variant R356C is located in exon 
13 in a region controlling GLIS3 stability through its interaction with Cullin 3 [39]. We 
initially tested the molecular consequences of the non synonymous variants in INS1 and 
PC12 neuronal cells transfected by the GK or the reference (Brown Norway, BN) allele of 
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Glis3. Transcription patterns of Fbxw11, Disc1, Dock7, Atg7 and Nxph2 were similar in INS1 
cells transfected with GK and control alleles of Glis3, whereas the GK allele of Glis3 induced 
marked downregulation of the expression of Atg4a, Baiap2, Otop2 and Phactr1 (p<0.05), a 
gene associated with coronary artery disease (Figure 4A). GLIS3-mediated expression 
regulation of Disc1 and Znrf2 in PC12 cells was not affected by the GK Glis3 variants. In 
contrast, transfection of GK Glis3 in PC12 cells induced strong transcription changes of Atg7, 
Bicd1, Lamp5, Nxph2 and Baiap2, a gene encoding a brain-specific protein involved in 
insulin signalling [40] and neurodegenerative disease [41]. In addition, GLIS3-reactive 
expression of Atg4a was abolished in these cells (Figure 4B). 
We then investigated the potential impact of Glis3 naturally occurring variants in autophagy. 
Stimulatory effect of GLIS3 on LC3-II abundance and in LC3-II/LC-I ratio in INS1 cells 
remained significant when cells were transfected by GK allele of Glis3 (Figure 4C) as 
previously observed with BN Glis3 alleles (Figure 3C). In contrast, transfection of the GK 
allele of Glis3 in PC12 cells induced a sharp increase in the expression of LC3-I and LC3-II 
(Figure 4D), which contrasts with the inhibitory effect of the wild type allele of Glis3 on 
these markers in these cells (Figure 3D). 
We further complemented functional aspects of GLIS3 established in cell lines with ex vivo 
data derived from primary cultures of hippocampus neurons and pancreatic islets and in vivo 
experiments in congenic rats. 
3.6.  Effects of naturally-occurring polymorphisms in Glis3 on insulin secretion and 
neuron architecture  
To test the impact of GK DNA variants in Glis3 and associated gene transcription changes on 
insulin secretion and neuronal structural features, INS1 cells and primary cultures of rat 
hippocampus neurons were transfected by clones expressing the reference (BN) or GK allele 
of Glis3. Transfection of the GK allele of Glis3 led to increased basal production of insulin, 
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which is a classical phenotypic feature observed in the GK strain, and to blunted stimulation 
of insulin secretion in response to a glucose challenge in vitro (Figure 5A), thus confirming 
the functional role of these variants on insulin secretion. Reduced stimulated insulin secretion 
(16.7mM glucose) in INS1 cells transfected with the GK allele of Glis3 was marginally 
significant (p<0.05) when compared to glucose-stimulated untransfected INS1. Transfection 
of BN Glis3 had no morphological effects in neurons (Figure 5B,C), which contrasts with the 
effect of Glis3 in PC12, probably due to differences in cell systems used. In contrast, 
stimulated expression of GK Glis3 led to significant reduction in neuron soma size (Figure 
5B,C). We carried out further quantitative analysis of neuron morphology using the Sholl 
method, which determines the number of dendrite intersections for gradually increasing 
concentric circles from the soma centre. We were able to demonstrate that the GK variants of 
Glis3 are associated with significant reduction of both dendritic complexity (Figure 5D) and 
spine density (Figure 5E), which are key neuronal features in neurodegenerative diseases. 
These data support the biological role of Glis3 in the regulation of gene expression in neurons 
and demonstrate the strong impact of GK naturally occurring polymorphisms on β-cell 
function and on neurite growth and morphology. 
3.7.  The GK haplotype in BN.GK-1k congenics is associated with enhanced insulin 
secretion in vitro and in vivo and suggestive evidence of increased autophagy in brain and 
in pancreas 
To further validate our findings in an in vivo system, we analysed glucose-induced insulin 
secretion and autophagy in rats of the congenic strain BN.GK-1k, which contains a short 
genomic region of chromosome 1 (1.31Mb) of GK origin, including Glis3 and 13 additional 
genes, introgressed onto the genomic background of the BN strain (Figure 6A). Rats of the 
congenic strain exhibited a modest but statistically significant (p<0.01) increase in insulin 
secretion in response to glucose in vivo (Figure 6B). Basal insulin levels in vivo and in vitro 
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in isolated islets were similar in BN.GK-1k and BN rats (Figure 6B,C). In vitro insulin 
secretion by islets isolated from BN rats was stimulated by 12mM and 20mM glucose. 
Glucose stimulated insulin secretion in vitro by incubated islets was higher in BN.GK-1k 
congenic rats than in BN controls and this effect was statistically significant (p<0.05) in 
response to 20mM glucose (Figure 6C). 
We then analysed markers of autophagy in total pancreas and whole brain in BN, GK and 
BN.GK-1k rats. Conversion of LC3 was significantly increased in GK pancreas (p=0.0001) 
and brain (p=0.04) when compared to BN controls (Figure 6D,E). This effect was replicated 
in BN.GK-1k congenic rats, which exhibited significantly higher conversion of LC3 than BN 
controls in both pancreas (p=0.023) and brain (p=0.019) (Figure 6D,E). The effect of GK 
variants of Glis3 on the stimulation of autophagy is conserved in the pancreas and whole 
brain of GK and congenic rats (Fig 6D,E), whereas discordant results are obtained in INS1 
and PC12 transfected with the GK alleles of Glis3 (fig3C,D), suggesting differential 
regulation at the organ level and in cultured cells. 
Collectively, these data provide in vivo experimental validation of our in vitro results and 
suggest that Glis3 variants may account for GK phenotypes originally mapped in GKxBN F2 
cross.  
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4. Discussion 
We have established a genome-wide inventory of DNA binding sites for the transcription 
factor GLIS3 in insulin secreting cells, which were often located in the close vicinity of loci 
associated with metabolic and neurological disorders in GWAS and genes involved in 
autophagy and neuron function. We confirmed experimentally the role of GLIS3 on gene 
transcription in β-cells and neurons. Naturally-occurring non synonymous variants in Glis3 in 
the GK model of type 2 diabetes (T2D) were associated with enhanced insulin secretion in 
vivo and in vitro, deteriorated morphology of hippocampus neurons, differential expression of 
key autophagy genes in insulin secreting cells and in neurons and up-regulated autophagy 
marker in brain and pancreas. 
Genome-wide occupancy data of GLIS3 in INS1 cells allowed prediction of a comprehensive 
collection of target genes of this transcription factor, which complements information from 
gene expression studies in experimental systems. Our data confirm the documented 
regulation of SLC2A2 [28, 42], which occurs through its direct interaction with DNA 
elements at this locus. The existence of G3BS at the PDX1 locus is consistent with data from 
our group showing that GLIS3 regulates PDX1 expression [28], but contradicts other reports 
that failed to show an effect of GLIS3 on PDX1 expression [35, 42]. In addition, we did not 
find evidence of statistically significant enrichment of G3BS for genes known to be regulated 
by GLIS3 (insulin, neurogenin 3, cyclin D2) [26, 42, 43]. In particular, we were unable to 
replicate significant enrichment for G3BS sequences identified by electrophoretic mobility 
shift assay (EMSA) upstream genes encoding insulin [26, 35] and neurogenin 3 [43], which 
may be explained by differences in cellular material and in experimental procedures used in 
the studies. These may also explain the lack of G3BS identified in our study close to the vast 
majority of genes shown to be regulated by GLIS3 [26, 35, 42] and differentially expressed in 
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pancreas of Glis3 mutant mice [26], suggesting that a proportion of the transcriptional effects 
of GLIS3 may be species specific or indirect consequences of Glis3 inactivation. 
Enriched DNA occupancy of GLIS3 at risk loci associated with metabolic and neurological 
diseases in GWAS supports frequent observations of genomic co-localization of risk genes 
for diseases characterised by distinct pathogeneses and target organs. This phenomenon of 
cross phenotype association [2] is well illustrated with T2D which shares common risk loci 
with autoimmune diseases [5], Crohn’s diseases [3], osteoporosis [44] and Alzheimer's 
disease (AD) [13, 45]. Even though causal relationship between T2D and AD is debated [46], 
T2D is a risk factor for AD and etiological connections between these diseases are supported 
by epidemiological and experimental evidence of mechanistic relationships [47, 48]. Patients 
with T2D have an increased risk of developing depression and AD when compared to 
individuals without T2D [49] and T2D is associated with more severe cognitive impairment 
in Parkinson disease [50]. Reciprocally, 80% of AD patients have glucose intolerance or T2D 
[49] and patients with schizophrenia exhibit greater risk of developing diabetes [51]. The 
identification of GLIS3 variants associated with diabetes and with an AD endophenotype 
[13], evidence of mental impairment in GLIS3 mutated patients [16, 17] and unpublished 
transcriptome data suggesting GLIS3 overexpression in hippocampus of patients with 
dementia (http://tinyurl.com/j83hcby), indicate that GLIS3 is highly relevant to the concept 
of cross phenotype association and shared etiology of complex diseases. Remarkably, the risk 
SNPs in GLIS3 associated with diabetes (type 1 and type 2) and related traits are not in 
linkage disequilibrium and therefore are independent from the SNP associated with AD 
endophenotype, suggesting that distinct GLIS3-reactive mediators may regulate metabolic 
and neurological traits. 
Pathway analysis of genes associated with G3BS suggested a potential role of Glis3 in 
neuropathologies and in autophagy. Even though pathway enrichment was not significant 
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when corrected for multiple testing, and the significance of the effects was therefore only 
suggestive, these analyses provided functional information and raised hypotheses that can be 
tested experimentally. Transcription regulation of key genes involved in these pathways was 
analysed experimentally following Glis3 transfection in insulin-secreting (INS1) and 
neuronal (PC12) cells. Even though patterns of gene transcription in response to GLIS3 
stimulation are generally conserved in INS1 and PC12, DISC1 is the only GLIS3 target 
significantly differentially expressed in both systems. This suggests different chromatin 
conformation at the tested loci in β-cells and neurons and the involvement of different 
mediators in these cells, which may have specific physiological consequences. 
Down-regulated expression of Disc1 upon Glis3 overexpression was a striking illustration of 
the conserved role of Glis3 in β-cells and neurons. DISC1 regulates neuronal development 
and synapse formation [52, 53] and DISC1 variants have been consistently implicated in 
schizophrenia, bipolar disorder, major depression and autism [52]. Interestingly, Disc1 
downregulation in mice results in decreased β-cell proliferation, glucose intolerance, reduced 
insulin secretion and Pdx1 expression [54]. Other genes involved in neuron function and 
neuropathologies (Grik1, Grik3, Ube3a, Grinl1a, Sptlc1, Dyrk1a, Rimklb) are associated with 
G3BS and contribute to enrichment of the neuron biological pathway. Glutamate receptors 
GRIK1 and GRIK3 modulate synaptic transmission and are associated with epilepsy, 
schizophrenia, AD and depressive disorder [55]. The E3 ubiquitin ligase UBE3A is critical 
for the processes of learning, memory and synaptic plasticity, and deficient expression of the 
maternal copy in the brain causes Angleman Syndrome, a neurodevelopmental disorder 
combining intellectual disability and seizures [56]. GRINL1A, SPTLC1 and DYRK1A are 
differentially expressed in brain of patients with AD [57-59] and RIMKLB is involved in 
schizophrenia through the regulation of N-acetyl-aspartylglutamate synthesis [60]. 
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Autophagy is a common mechanism in β-cells and neurons in diabetes and neuropathologies. 
Enhanced autophagy is associated with β-cell death in T2D [61] and may protect β-cells 
against palmitate-induced apoptosis [37]. It suppresses neurite degeneration in PC12 cells 
[62] and has a neuroprotective role in AD [63]. These data suggest context-dependent 
regulation of autophagy in β-cells and neurons and may explain the broad and contrasting 
effects of GLIS3 stimulation on autophagy marker LC3II/I in INS1 and PC12 in the present 
study, which remains to be further characterised by the analysis of autophagy flux. The most 
significant autophagy gene which is differentially regulated in GLIS3 transfection 
experiments is ATG7, an essential component in autophagosome formation. Investigations in 
organ-specific Atg7 knock-out mice demonstrated its causative role in glucose intolerance, 
impaired islet structure and neurodegenerative symptoms [64]. The Pdx1 deficient mouse 
model of reduced insulin secretion and β-cell mass also exhibits increased autophagy [65]. 
The function we propose for GLIS3 in the control of autophagy underlines the complex 
interplay between cellular mechanisms of recycling or elimination of proteins and 
cytoplasmic organelles [66] in diabetes and neurodegenerative diseases, including retromer, a 
cellular mechanism of protein recycling from vacuolar endosomes [67] involving risk genes 
(SORCS1, VPS10) for T2D and AD [68, 69], and apoptosis which is stimulated by Glis3 
knock-down in INS1 and primary β-cells [28]. 
Analysis of the functional consequences of amino-acid changes in GLIS3 caused by GK 
naturally occurring genetic polymorphisms provided evidence of consistent increased 
autophagy markers LC3II/I in both rat brain and pancreas. Contrasting effects of GLIS3 on 
LC3 levels in INS1 and PC12 coincide with differential transcriptional response of Atg7 and 
Atg4a to stimulation by the BN or GK alleles of Glis3 in these cells, which suggests the 
involvement of different molecular mediators in GLIS3 function in these cells. Genetic 
polymorphisms in Glis3 have also been reported in the NOD mouse model of T1D to 
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contribute to β-cell mass reduction and increased β-cell apoptosis in this strain [70]. In the 
GK rat, the variants R356C and S851P in GLIS3 may account for the quantitative trait locus 
for enhanced insulin secretion which we identified in a GKxBN F2 cross to a region of 
chromosome 1 encompassing Glis3 [32], validated in the congenics BN.GK-Nidd/gk1 [31], 
and fine mapped both in an intercross from BN.GK-Nidd/gk1 rats [71] and in the congenic 
strain BN.GK-1k in the present study. Their possible roles on increased autophagy in 
pancreas and brain remain to be replicated in β-cells and in hippocampus in BN.GK-1k and 
in substrains narrowing the congenic interval to Glis3. These variants may also account for 
brain anomalies suggesting neurodegeneration in the GK rat, including neuronal loss in the 
cerebral cortex [72] and decreased dendritic spine density in the hippocampus [73]. 
Increased autophagy and co-occurring enhanced insulin secretion mediated by GK GLIS3 
variants may represent a mechanism observed in starved INS1 cells [74] that compensates for 
dramatic β-cell mass reduction in GK rats. We cannot rule out a contribution of other variants 
in the 1.31Mb GK segment in BN.GK-1k to the regulation of insulin secretion and 
autophagy. Results from our genome sequencing of the GK/ox colony [38] identified over 
3,400 DNA polymorphisms in the GK genomic interval of the congenic strain BN.GK-1k 
(Table S6), including four non synonymous variants in AK3 (L123Q), RCL1 (S400I), JAK2 
(T469R) and RLN1 (S126G), which might impact phenotypic features of BN.GK-1k rats. 
Collectively, results from both cell transfection with GK Glis3 and phenotype analyses in 
BN.GK-1k support cross-phenotype associations of GLIS3 in GWAS for metabolic diseases 
and neuropathologies. 
5. Conclusions 
Our results provide experimental evidence for a pleiotropic role of GLIS3 in diabetes and 
neuropathologies and its function in β-cells and neurons. These findings require validation 
through replication of the ChIPseq experiment with other GLIS3 antibodies and other β-cell 
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models, and further functional characterisation of GLIS3, including deeper analyses of 
autophagy mechanisms by measuring autophagy flux. Our data suggest that GLIS3 may be a 
central regulatory hub for trans-nosology drug development, which may have important 
implications in the treatment of diabetes and its comorbidities. 
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Legends to figures 
Figure 1. Outlined experimental design and methods applied to the identification of 
GLIS3 target genes in INS1 insulin secreting cells and the characterisation of it 
function. 
Figure 2. Outlined output of ChIP-Seq analysis of GLIS3 binding sites (G3BS) in INS1 
cells and relevance of GLIS3 and its targets to metabolic and neurobehavioural 
diseases. Read-enriched regions from the ChIP-Seq experiment derived with an ABCAM 
antibody were analysed using MACS2 (https://pypi.python.org/pypi/MACS2/) and sequences 
were aligned to the rat reference genome assembly (Rnor_5.0 release 74) to identify the 
closest gene. a. Profile of Glis3 marks with respect to nearby transcription start site (TSS). 
Input is represented by the dashed red line and the solid blue line represents the IP. b. 
Dimont, RSAT (Peak-motifs) and GimmeMotifs tools were used to search for conserved 
motifs in peak sequences and CompleteMotifs identified a single consensus motif sequence 
for G3BS. c. Evidence of GLIS3 expression in hippocampus assessed by in situ hybridization 
(source: The Allen Mouse Brain Atlas, http://mouse.brain-map.org/gene/show/86346). d. 
Localisation of GLIS3 in pancreatic islets assessed by immunocytochemistry. Serial staining 
(brown) of pancreas sections shows the localisation of insulin, glucagon and Glis3, using a 
custom made antibody (Eurogentec). Red arrow indicates an area specifically stained for 
glucagon and white arrows areas of staining for both GLIS3 and insulin and demonstrating 
co-localisation. e. Association of loci linked to GLIS3 binding sites with disease phenotypes 
in GWAS (www.ebi.ac.uk/gwas). 
Figure 3. Effects of GLIS3 on the expression of genes close to G3BS and autophagy in 
insulin-secreting cells and neurons. Expression of genes associated with G3BS was tested 
by quantitative RT-PCR in INS1 (a) and NGF-PC12 (b) cells overexpressing the wild-type 
(Brown-Norway, BN) allele of Glis3 (INS1-GLIS3 and PC12-GLIS3). Results are expressed 
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in 2-DDCT (vs GAPDH and vs controls cells transfected with empty plasmid) on 4 biological 
replicates. LC3-I and -II protein levels and ratio were determined in INS1 cells (c) and in 
NGF-PC12 cells (d) transfected with a control plasmid (INS-CTL, PC12-CTL) and with a 
plasmid expressing Glis3 (INS1-GLIS3, PC12-GLIS3). SiRNA-mediated Glis3 expression 
knock-down in INS-1E cells and representative blots and densitometry of LC3-I and LC3-II 
protein expression normalized by the housekeeping protein α-tubulin in INS-1E cells 
transfected with control or GLIS3 siRNA (e). Results are means ± SEM (n = 5). Effect of 
carbamazepine on GLIS3 knock down-mediated apoptosis in INS1-E cells (n=7) (f). Results 
are means ± SEM. *p<0.05, **p<0.01, *** P<0.001 significantly different to controls; ### 
P<0.001 significantly different to siGLIS3 or $$ P<0.01 significantly different to siGLIS3 
with carbamazepine. 
Figure 4. Impact of Glis3 polymorphisms on gene expression and the regulation of 
autophagy in insulin secreting cells and neurons. Expression of genes associated with 
G3BS was tested by quantitative RT-PCR in INS1 (a) and NGF-PC12 (b) cells 
overexpressing the wild-type (Brown-Norway, BN) allele or the GK allele of Glis3. 
Quantitative RT PCR results are expressed in 2-DDCT (vs GAPDH and vs controls cells 
transfected with empty plasmid) on 4 biological replicates. *p<0.05 significantly different to 
controls. c. LC3-I and -II protein levels and LC3-I to LC3-II ratio in INS1 cells transfected 
with a control plasmid (INS1-CTL) and with a plasmid expressing the GK allele of Glis3 
(INS1-GLIS3GK). d. LC3-I and -II protein levels and ratio in NGF-PC12 cells transfected 
with a plasmid control (PC12-CTL) and with a plasmid expressing the GK allele of Glis3 
(PC12-GLIS3GK). Data are reported as mean ± SEM based on 6 biological replicates. 
*p<0.05, **p<0.01 significantly different to controls. 
Figure 5. Effects of naturally occurring polymorphisms of Glis3 in the GK strain on 
insulin secretion in INS cells and neurite complexity in cultured hippocampus neurons. 
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a. Glucose stimulated insulin secretion in INS1 cells. Cells were transfected with an empty 
plasmid (CTL), or plasmids expressing Glis3 alleles from either the Brown Norway control 
strain (GLIS3) or the diabetic GK strain (Glis3GK) (n=9 per group). Data are means ± SEM. 
*p<0.05, ***p<0.001 significant differences in insulin secretion between glucose 
concentations of 16.7mM and 2.8mM (basal). b. Hippocampal neurons (DIV21) were co-
transfected with GFP and either control plasmids or cloned cDNAs expressing the BN or GK 
alleles of Glis3, and imaged by confocal microscopy after 5 days. c. Quantification of soma 
size. Each soma where delimited manually with ROI and the area were extracted (n=30). d. 
Sholl analysis. The number of dendrite branches crossing concentric circles around the soma 
was automatically counted using Fiji Sholl analysis plugin (n=30). e. Spine density per µm 
quantification. Data are means ± SEM; *p<0.05, **p<0.01 significantly different to controls. 
Figure 6. In vivo and in vitro insulin secretion and autophagy in a rat congenic strain 
carrying GK Glis3 variants. Details of the GK genomic region (highlighted in yellow) 
introgressed onto a BN background in the congenic BN.GK-1k (a). Glucose stimulated 
insulin secretion in vivo (b) and in vitro in isolated islets (c). Autophagy in total pancreas (d) 
and whole brain (e). Number of replicates are indicated in the bars. Data are means ± SEM; 
*p<0.05, **p<0.01, ***p<0.001 significantly different to BN controls. 
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Table 1. Biological pathway enrichment analysis of genes encompassing GLIS3 binding sites. Analyses were carried out with Ingenuity Pathway 
Analysis (IPA) (A) and with DAVID (B) (david.abcc.ncifcrf.gov) using Gene Ontology (GO) terms. For each pathway or function genes 
contributing to enrichment are given. P-values are not corrected for multiple testing. ES, Enrichment Scores. 
A- Ingenuity Pathway Analysis  
Top Functions (Ranking) Score Focus molecules 
Endocrine System Development and Function, 
Molecular Transport, Protein Synthesis (1) 
46 ABCC2, ARF1, BMP2K, DISC1, DYRK1A, EPHB1, ITPR1, KCNN4, MAN2A1, MMD, MSR1, 
MUC5AC, PAQR3, PDX1, PHACTR1, SLC2A2, TAF11, TRPC4, TSPAN9, VAV1, ZBTB20 
Endocrine System Disorders, Metabolic 
Disease, Cell Morphology (2) 
35 ANGPTL3, ATG7, BAIAP2, EZH2, GRIK1, GRIK3, INSR, LPHN3, LZTS1, MEOX1, NLRP12, 
NSF, PDX1, RP2, SLC2A2, SLIT3, STXBP4 
Nervous System Development and Function, 
Tissue Morphology, Cancer (3) 
28 ANKS1A, CGGBP1, COL14A1, ECHDC1, FAM5C, GAA, KCNG1, KCTD3, NEIL3, RIMKLB, 
RPS6KC1, STXBP6, ZNRF2 
Endocrine System Disorders, Gastrointestinal 
Disease, Hereditary Disorder (4) 
26 ANKRD10, ATG4C, CDO1, CGGBP1, COX15, CYB561, FAM105A, FECH, FOXP1, 
GALNT11, GFPT1, LRIF1, LRP5, MANBAL, SLC22A12, SPTLC1, TCOF1 
Endocrine System Disorders, Metabolic 
Disease, Carbohydrate Metabolism (5) 
24 GPR12, HSD17B6, KCNJ6, LAMP5, MAML2, PLA2G12B, PPP1R12B, SLC2A2 
 
 
    B- DAVID     
GO id GO Term (Cluster) P-value ES Contributing genes 
6914 Autophagy (1) 0.011 1.46 ATG12, ATG4C, ATG7 
45202 Synapse  (2) 0.016 1.43 PHACTR1, LZTS1, GRIK1, GRIK3, ERC2, INSR, NSF, ITPR1 
44463 Cell projection part (3) 0.008 1.37 LZTS1, GRIK1, SLC22A12, GRIK3, SLC2A2, NSF, GNAT3 
6811 Ion transport (4) 0.009 1.22 TRPC4, KCNJ6, GRIK1, SLC22A12, GRIK3, KCTD3, ABCC2, MUC5AC, NSF, 
KCNIP4, ITPR1 
5216 Ion channel activity (4) 0.020  TRPC4, KCNJ6, GRIK1, GRIK3, KCTD3, KCNIP4, ITPR1 
48878 Chemical homeostasis (4) 0.035  FECH, GRIK1, GRIK3, PDX1, ABCC2, ANGPTL3, INSR, ITPR1 
5887 Integral to plasma membrane (6) 0.012 1.15 TRPC4, FLT1, GRIK1, GRIK3, KCTD3, ABCC2, INSR, EPHB1 
7267 Cell-cell signaling (7) 0.017 1.06 HRH1, GRIK1, GRIK3, PDX1, ERC2, NSF, EPHB1 
42995 Cell projection (7) 0.028  LZTS1, GRIK1, SLC22A12, GRIK3, BAIAP2, SLC2A2, KATNB1, RHEB, ERC2, 
NSF, GNAT3 
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7268 Synaptic transmission (7) 0.049  HRH1, GRIK1, GRIK3, ERC2, NSF 
5525 GTP binding (8) 0.014 1.01 ARF2, DOCK9, RHEB, DOCK7, RAB38, INSR, GNAT3 
32555 Purine ribonucleotide binding (10) 0.017 0.92 FLT1, RGD1561667, DOCK9, DOCK7, EPHB1, GNAT3, RFC3, ARF2, ASCC3, 
DGKG, DYRK1A, RGD1560718, BMP2K, RHEB, RAB38, ABCC2, INSR, NSF 
4713 Protein tyrosine kinase activity (10) 0.040  FLT1, DYRK1A, INSR, EPHB1 
6289 Nucleotide-excision repair (16) 0.039 0.78 RFC3, NEIL3, BRCA2 
48878 Chemical homeostasis (19) 0.035 0.71 FECH, GRIK1, GRIK3, PDX1, ABCC2, ANGPTL3, INSR, ITPR1 
31667 Response to nutrient levels (23) 0.032 0.66 ATG12, ATG7, BRCA2, PDX1, MUC5AC, INSR 
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Table 2. Comparative mapping analysis of GLIS3 binding sites in the human genome. Human orthologs flanking 
GLIS3 binding sites (G3BS) were searched in the GWAS archive (www.ebi.ac.uk/gwas) for published genetic 
association with diseases and phenotypes. All GWAS loci that we searched in this catalogue were statistically 
significant, ie. supported by a p-value <1.0 x 10
-5
 in the overall (initial GWAS and replication) population Reference 
to the G3BS clusters defined in Table S2 is reported in parentheses. Intermediate phenotypes were associated with 
relevant diseases and categorised as described in Table S4. GWAS signals for both cardio-metabolic and 
neurodegenerative/neurobehavioral phenotypes are underlined.  
 
Cardio-metabolic diseases 
Type 2 diabetes: SLC2A2 (28), CHL1 (52), TMEFF2 (85), PDX1/GSX1 (110), PPP2R2C (125), SPRY2 
(134), UHRF1BP1 (160) 
Obesity: RSPO3 (1), NLRP8 (8), c19orf18 (9), UBE3A (14), COX15 (25), TRPC4 (29), UNC5C (36), 
LPHN2 (37), NEGR1 (38), PAK7 (41), MACROD2 (42), CHL1 (52), ITPR1 (58), BICD1 (61), LINGO2 
(62), TLR4 (63), STXBP6 (70), TRIB1 (77), FAM84B (77), MAML2 (78), EPHB1/PPP2R3A (80), 
TMEM100/MMD (91), TOM1L1 (92), AATK/RPTOR (98), GRIK1 (100), SETD4 (101), DGKG (105), 
RFC3 (107), SLC46A3 (109), DPP10 (117), PPP1R12B (118), FGFRL1 (122), KCNIP4 (128), MRPS24 
(129), SPRY2 (134), NRG3 (137), DDX60L/PALLD (140), FHOD3 (148), SCGB3A2/SPINK1 (149), 
KCNN2 (149), RPS14 (151), CAMK2A (151), ANKS1A (160), GRIK2 (163) 
Adipose tissue variables: ADCY2 (2), ARRDC4 (16), NEGR1 (38), FOXP1 (57), TRIB1 (77), FER (86), 
BACH1 (100)  
Insulin resistance and metabolic syndrome: DYRK1A (102), INSR (108), ZNF644 (123), GAS1 (145), 
TOX3 (157) 
Lipid metabolism: PAPD7 (2), Cd36 (50), PRMT8 (60), TRIB1 (77), RUNX1 (101), 
ATP6V1B2/SLC18A1 (139), LPAR2 (139), CNTNAP4 (158) 
Cardiovascular phenotypes: UBE3A (14), XRCC4 (26), TNIK (28), LRRIQ3 (38), MACROD2 (42), 
Cd36 (50), CHL1 (52), DOCK7/ANGPTL3 (64), PPAP2B (65), TRIB1 (77), MYO6 (79), TMEFF2 (85), 
GRIK1/CLDN17/CLDN8 (100), INSR (108), FLT1 (109), CNTNAP5 (115), FAM5c (119), FHIT (133), 
NRG3 (137), LZTS1/ATP6V1B2 (139), NEIL3 (141), RBPMS (143), ARHGEF7 (144), PHACTR1 (147), 
KCNN2 (149), POLR2M (154), DISC1 (159), ANKS1A (160), GRIK2 (163) 
NAFLD and liver metabolism: RSPO3 (1), SLC2A2 (28), MACROD2 (42), TRIB1 (77), SLC46A3 
(109), DDX60L (140), ATP8B1 (152) 
Neurodegenerative and neurobehaviour 
Alzheimer's disease: ZNF224 (10), CD33 (13), RRAS2 (20), STK24 (20), PPAPDC1A (21), UNC5C 
(36), rs7638995 (56), MAN2A1 (86), RP11-572M11.4 (104), RFC3 (107), DMXL1 (126), DISC1 (159) 
Schizophrenia: TNIK (28), GRIK3 (66), FBXO11 (67), ITSN2 (68), STXBP6 (70), JRKL (78), 
CNTNAP5 (115), NRG3 (137), PALLD (140), TUSC3 (142) 
Bipolar disorder: PRKAG2 (49), rs11123306 (117) 
Autism: MACROD2 (42) 
Attention deficit hyperactivity disorder: FRMD1 (4), FOXP1 (57), SLC6A1 (59), GRIK1 (100), 
PDX1/GSX1 (110), FHIT (133), ATP8B1 (152) 
Major depressive disorder: EPN1 (109), FHIT (133), LZTS1/ATP6V1B2/SLC18A1 (139) 
Autism, Attention deficit hyperactivity disorder, Bipolar disorder, Major depressive disorder and 
Schizophrenia combined: ELTD1 (37), GRIK1 (100) 
Bipolar disorder and Schizophrenia combined: LRRIQ3 (38), ASTN2 (63), ERC2 (136), SPTLC1 
(146) 
Brain and central nervous system: RSPO3 (1), KIF25 (5), MACROD2 (42), RPN2 (45), SUMF1 (58), 
BICD1 (61), CRHR1 (94), KCNJ6 (102), ZNF326 (123), DISC1 (159) 
Other neurological and neurobehavioural phenotypes: ARRDC4 (16), STK24 (20), FLG (32), LPHN2 
(37), NXPH2 (39), SPOPL (39), MACROD2 (42), PLXNA4 (51), CHL1 (52), VGLL4 (59), DBC1 (63), 
LAMB4/NRCAM (70), NSF (94), FLT1 (109), USP12 (111), CNTNAP5 (115), DGKQ/GAK (122), 
LPHN3 (125), ARAP2 (127), KCNIP4 (128), COBL (130), FHIT (133), TUSC3 (142), GTF2E2 (143), 
PHACTR1 (147), FHOD3 (148), TOX3 (157), CNTNAP4 (158), DISC1 (159), GRIK2 (163), ASCC3 
(163) 
Autoimmunity inflammation and infectious diseases: FRMD1 (4), TTLL2 (4), RAB38 (19), RPS6KA4 (23), 
LPXN/CNTF (24), FLG (32), NEGR1 (38), MACROD2 (42), FRMD4B (56), LINGO2 (62), DBC1 (63), 
TRIB1 (77), MAML2/JRKL (78), PLCL2 (84), TMEM232 (86), RUNX1 (101), DYRK1A (102), USP12 
(111), ANXA3 (124), COBL (130), UBAC2/GPR18/GPR183 (135), VEGFC (141), DAPK1 (145), 
NEDD9 (147), ATP8B1 (152), CYLD (157), CNTNAP4 (158), UHRF1BP1 (160) 
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Cancer: ECHD1 (1), "ADCY2 (2), PAPD7 (2), LPXN (24), CHL1 (52), ITPR1 (58), TEAD4 (60), BICD1 
(61), MAML2 (78), STXBP4/COX11 (92), BACH1 (100), GRIK1 (100), RUNX1 (101), Zbtb20 (104), 
BRCA2 (106), SFPQ (114), TSN (116), LGR6 (118), UBAC2/GPR18/GPR183 (135), DAPK1 (145), 
TOX3 (157), DISC1 (159), ANKS1A (160) 
Height: SHOX2 (30), PDIA4 (53), FBLN5 (71), SYN3/TIMP3 (75), MAML2 (78), SENP6 (79), FER (86), 
FBXW11 (88), SLIT3 (89), TMEM100/MMD (91), INSR (108), ZCCHC6 (145), ANKS1A (160) 
Renal function: RSPO3 (1), SLC22A12 (23), CST9 (43), PRKAG2 (49), HLF (91), GRIK2 (163) 
Hematology: NEGR1 (38), PLCB4 (41), SHH (47), PRKAG2 (49), Cd36 (50), STXBP6 (70), HSD17B6 (73), 
EPHB1/PPP2R3A (80), MYH15 (103), PCGF3 (122) 
Bone: RSPO3 (1), CHL1 (52), SOST (93), CRHR1 (94), IDUA (122), ERC2 (136), PHACTR1 (147), CYLD 
(157) 
Eye: POSTN (29), CTSS (33), SRC (45), SHH (47), SYN3/TIMP3 (75), FAM84B (77), MAML2 (78), INSR 
(108), FHIT (133), NRG3 (137) 
Others: STK24 (20), MUC2 (22), RAP1GDS1 (36), ELTD1 (37), NXPH2 (39), ITPR1 (58), SLC6A1 
(59), BICD1 (61), PPAP2B (65), PRIM1 (73), VAV1/EMR1 (81), ACE (95), C3Orf38 (99), RUNX1 
(101), INSR (108), RNF212 (122), ANXA3 (124), LPHN3 (125), FHIT (133), SPRY2 (134), LZTS1 
(139), TUSC3 (142), ARHGEF7 (144), GRIK2 (163) 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Highlights 
 GLIS3 binding sites in insulin secreting cells share the motif wrGTTCCCArTAGs  
 GLIS3 controls the expression of genes involved in autophagy and neuron function 
 Glis3 sequence polymorphisms in the diabetic GK rat alter β-cell function 
 Glis3 variants in the GK rat modify neurogenesis in hippocampus neurons 
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